Related Experiment Video

Updated: May 31, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

Sophie Roca, Amandine Quivy, Marine Gross-Goupil

    Acta Oncologica (Stockholm, Sweden)
    |July 6, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
    10:27

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

    Published on: July 25, 2020

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
    11:27

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

    Published on: April 29, 2014

    Related Experiment Videos

    Last Updated: May 31, 2026

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
    06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
    10:27

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

    Published on: July 25, 2020

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
    11:27

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

    Published on: April 29, 2014

    Related Concept Videos

    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...

    Articles linked to this work by shared authors, journal, and citation graph.

    Impact of resection bed management on postoperative outcomes after Robot-Assisted Partial Nephrectomy : a retrospective French Nationwide Study (UroCCR 215).

    World journal of urology·2026

    Low diagnostic yield of routine preoperative chest CT in patients undergoing partial nephrectomy: A national cohort study using UroCCR data (UroCCR n°216).

    BJUI compass·2026

    Automatic Kidney Image Segmentation During Robot-Assisted Partial Nephrectomy Using a Deep Learning Model Based on a Multiannotator Dataset: Model Development and Validation Study.

    JMIR medical informatics·2026

    Robot-Assisted Versus Open and Laparoscopic Radical Nephrectomy with Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

    Cancers·2026

    Impact of Moses technology on HoLEP day-case success rate: a monocentric matched paired cohort study.

    World journal of urology·2026

    Off-clamp and on-clamp robotic-assisted partial nephrectomy in ischemia-sensitive patients: a multicenter propensity score-matched study (RAPN OFF-CLAMP study - UroCCR 187).

    Minerva urology and nephrology·2026

    Treatment attrition and outcomes of myeloma patients in Finland: a real-world study.

    Acta oncologica (Stockholm, Sweden)·2026

    Detection of circulating tumor HPV-DNA in patients with HPV-positive sinonasal and nasopharyngeal carcinoma.

    Acta oncologica (Stockholm, Sweden)·2026

    Continuous intrathecal therapy for refractory cancer pain: A systematic review and meta-analysis focusing on partially implanted devices.

    Acta oncologica (Stockholm, Sweden)·2026

    Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts.

    Acta oncologica (Stockholm, Sweden)·2026

    Tools for providing information to patients about high-tech medical resources for treatment of cancer.

    Acta oncologica (Stockholm, Sweden)·2026

    Primary treatment and relative survival by stage and age in vaginal carcinoma: a population-based SweGCG study.

    Acta oncologica (Stockholm, Sweden)·2026

    Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report.

    Current oncology (Toronto, Ont.)·2026

    Up-Front Immune Checkpoint Inhibitors in Patients with Multiple Synchronous Primary Tumors, Including dMMR/MSI-H Gastrointestinal Malignancies: A Case Series and Review of the Literature.

    Current oncology (Toronto, Ont.)·2026

    Advanced Therapies for Diabetic Kidney Disease: A Critical Review of Gene-, RNA-, and Cell-Based Strategies to Address Residual Risk.

    Diseases (Basel, Switzerland)·2026

    Association of DNA Copy Number Aberrations with Organ-Specific Metastasis in Luminal B HER2-Negative Breast Cancer.

    Diseases (Basel, Switzerland)·2026

    Carboxymethylcellulose/Hyaluronic Acid Hybrid Nanoconjugates: Toward Multifunctional Platforms for Melanoma Skin Cancer Theranostics.

    Gels (Basel, Switzerland)·2026

    Antagonistic TGR5 and FXR Signaling Shapes STAT1-Dependent Interferon Responses in Intestinal Epithelial Cells.

    Cells·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us